Should You Buy Syra Health Corp. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Syra Health Corp. (SYRA) carries a solid Quality of Company rating of 5.9/10. Trading at $0.80, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 1 of 2 CirclFi valuation models project upside for Syra Health Corp. (SYRA) at $0.80 — the models are evenly split, with a Quality Score of 5.9/10 and Value-Trap risk of 33/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Syra Health Corp. (SYRA) in 2026?
What Is the Bull Case vs the Bear Case for Syra Health Corp. (SYRA)?
| Bull case — $1.07 target (+33.8%) | Bear case — $0.03 target (-96.9%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $1.07 (+33.8%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.03 (-96.9%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +130.7% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
How Does SYRA Compare to Its Medical Care Facilities Peers?
Valuation data pages: CCM · AGL · MCTA · GBCS · AIRS · AMS · CMPS · THC · JYNT · ADUS · NHC
Which Other Stocks Score Like SYRA on Quality?
Closest companies to SYRA’s Quality of Company score of 5.9/10, across all industries.
- AEVA — Aeva Technologies, Inc. (QOC 5.9) · analysis
- PBSV — Pharma-Bio Serv, Inc. (QOC 5.9) · analysis
- ARCC — Ares Capital Corporation (QOC 5.9) · analysis
- SKYH — Sky Harbour Group Corporation (QOC 5.9) · analysis
- BETA — BETA Technologies, Inc. (QOC 5.9) · analysis
- ABEO — Abeona Therapeutics Inc. (QOC 5.9) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Care Facilities Screens Does SYRA Appear In?
So Is Syra Health Corp. (SYRA) Worth Buying in 2026?
Our models don't have a clear verdict on Syra Health Corp.. At $0.80 vs. $0.55 median fair value, the median upside of -31.5% masks significant model disagreement (+130.7% spread). With quality at 5.9/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. Syra Health Corp.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About SYRA Stock?
Should I buy SYRA stock right now?
Based on CirclFi's multi-model analysis, 1 of 2 models see upside for SYRA at $0.80. The models are divided, which means the investment case depends heavily on your assumptions about Syra Health Corp.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Syra Health Corp.?
Key risks include: limited model coverage (2/13 active), reducing analytical confidence; wide model disagreement (4168% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Care Facilities companies. Always diversify and consult a financial advisor.
How does SYRA compare to its competitors?
Among Medical Care Facilities peers, SYRA holds a Quality Score of 5.9/10. Comparable companies include CCM (QOC 6.1), AGL (QOC 5.9), MCTA (QOC 6.1). The relative ranking helps investors identify whether SYRA offers better fundamental quality than alternatives in the same sector.
Is SYRA a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. SYRA's Quality Score of 5.9/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy SYRA at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $0.03 to $1.07. At $0.80, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for SYRA.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad